

Improving models of chronic lymphocytic leukemia

April 7 2016

Chronic lymphocytic leukemia (CLL) is a common form of adult leukemia that results in the progressive expansion of abnormal lymphocytes. The cell type that gives rise to CLL is still unclear, though evidence suggests that a subset of immature B cell lymphocytes is transformed during development. Because of the heterogeneity of this cancer, it has not been possible to create a mouse model that faithfully recapitulates all aspects of this disease.

In this issue of *JCI Insight*, Nicholas Chiorazzi and colleagues at the Feinstein Institute for Medical Research sought to understand a model of CLL in which patient cancer cells are transplanted into immunocompromised mice. They previously showed that patient cells initially engrafted into mice and mimicked the disease, but the engraftment did not persist long term. In this study, they show that human malignant B cells from CLL patients differentiate into antibody secreting plasma cells in their murine model in the presence of patient-derived T cells.

Their findings reveal why [cancerous cells](#) are not maintained in their [mouse model](#) and suggest the possibility that therapies promoting differentiation could merit further exploration for CLL.

More information: Piers E.M. Patten et al. Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6–deficient process, *JCI Insight* (2016). [DOI: 10.1172/jci.insight.86288](https://doi.org/10.1172/jci.insight.86288)

Provided by Journal of Clinical Investigation

Citation: Improving models of chronic lymphocytic leukemia (2016, April 7) retrieved 18 April 2024 from <https://medicalxpress.com/news/2016-04-chronic-lymphocytic-leukemia.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.